TARS Q3 2022 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$211,000

Operating Income

-$23M

Net Income

-$23M

EPS (Diluted)

$-0.84

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$236M

Total Liabilities

$34M

Stockholders' Equity

$203M

Cash & Equivalents

$169M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$1M	-100.0%
Gross Profit	-$211,000	$1M	-118.0%
Operating Income	-$23M	-$16M	-45.9%
Net Income	-$23M	-$16M	-43.4%